GSK2239633A   Click here for help

GtoPdb Ligand ID: 10416

Synonyms: compound 6 [PMID: 23409871] | GSK-2239633A
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: GSK2239633A is a arylsulfonamide class CC-chemokine receptor 4 (CCR4) antagonist. It binds the intracellular domain of the receptor, and therefore has an allosteric mode of action [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 159.17
Molecular weight 548.1
XLogP 2.9
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cccc2c1c(nn2Cc1cccc(c1)CNC(=O)C(O)(C)C)NS(=O)(=O)c1ccc(s1)Cl
Isomeric SMILES COc1cccc2c1c(nn2Cc1cccc(c1)CNC(=O)C(O)(C)C)NS(=O)(=O)c1ccc(s1)Cl
InChI InChI=1S/C24H25ClN4O5S2/c1-24(2,31)23(30)26-13-15-6-4-7-16(12-15)14-29-17-8-5-9-18(34-3)21(17)22(27-29)28-36(32,33)20-11-10-19(25)35-20/h4-12,31H,13-14H2,1-3H3,(H,26,30)(H,27,28)
InChI Key YTEVTHHGQMUPHC-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
GSK2239633A progressed to Phase 1 clinical evaluation for asthma, and although well tolerated, reaching CCR4 occupancy of >70% and inhibiting markers of CCR4 activation, development was not progressed further (see NCT01371812), likely due to unsuitably low bioavailability [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01371812 GSK2239633 FTIH Study Phase 1 Interventional GlaxoSmithKline